Josette Dudoit
Family · Honolulu, HINPI 1083846273
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,414 and has fallen 56.8% since, to $1,043 in 2025. Among family clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$1K
- AstraZeneca$1K
- Travere Therapeutics, Inc.$848
- Novartis$794
- Bayer$744
- GSK$643
- plus $2K from 14 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$7,14695%
- Education$2403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 42 | $1,440 |
| AstraZeneca | 43 | $1,022 |
| Travere Therapeutics, Inc. | 17 | $848 |
| Novartis | 47 | $794 |
| Bayer | 41 | $744 |
| GSK | 19 | $643 |
| Amgen | 39 | $619 |
| Novo Nordisk | 29 | $547 |
| Mallinckrodt Hospital Products Inc. | 17 | $306 |
| Ardelyx, Inc. | 7 | $145 |
| Calliditas Therapeutics US Inc. | 4 | $109 |
| Vifor Pharma, Inc. | 4 | $77 |
| Boehringer Ingelheim | 2 | $55 |
| Abbott | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Kyowa Kirin, Inc. | 1 | $33 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Cormedix Inc. | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,536 in reported general payments places this provider in the 95th percentile of 466 family providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 96 | $132,579 |
| VascepaIcosapent Ethyl | 145 | $110,970 |
| KerendiaFinerenone | 41 | $65,200 |
| Cinacalcet Hcl | 16 | $49,857 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $46,157 |
| VelphoroSucroferric Oxyhydroxide | 14 | $37,293 |
| JardianceEmpagliflozin | 19 | $27,585 |
| ProcritEpoetin Alfa | 16 | $14,369 |
| Sevelamer Carbonate | 48 | $14,326 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $14,251 |
| Carvedilol ErCarvedilol Phosphate | 13 | $4,853 |
| Allopurinol | 166 | $2,604 |
| Atorvastatin Calcium | 65 | $2,322 |
| Pravastatin Sodium | 78 | $2,313 |
| AliskirenAliskiren Hemifumarate | 15 | $2,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,022 | $178,736130 claims |
| BayerKerendia | $744 | $65,20041 claims |
| Boehringer IngelheimJardiance | $55 | $27,58519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family providers in Hawaii.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- John MosesHonolulu$24K
- Leif MarzHonolulu$11K
- Ia Lynne AranaHonolulu$9K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
- Tate KusatsuHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.